Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Gold Miners ETF (GDX) vs Incyte Corporation (INCY) Price & Performance

VanEck Gold Miners ETFTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

VanEck Gold Miners ETF vs Incyte Corporation — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: VanEck Gold Miners ETF and Incyte Corporation are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Incyte Corporation for 33 Days on average.

GDXINCY
Market Cap
$25.65B$22.85B
Volume
16,534,0461,927,029
52-Week High
$115.84$129.93
52-Week Low
$68.28$83.80
Typical Hold Time
76 Days33 Days
Sector
—Health
Enterprise Value
—$18.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Gold Miners ETF

GDX (VanEck Gold Miners ETF) trades at $86.74, up 1.5% on the day but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased stakes significantly.

The outlook remains cautious with technical indicators pointing bearish, though gold's resilience amid rising rates provides fundamental support. Key risks include interest rate sensitivity and metals price volatility, while the valuation gap between physical gold and miners presents a potential opportunity if gold maintains strength.

Incyte Corporation

Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.

Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GDX
43% Buy57% Sell
Avg holding period · 76 Days
INCY
100% Buy0% Sell
Avg holding period · 33 Days

Top news

Latest headlines on both assets

About VanEck Gold Miners ETF

The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.

Read more on GDX →

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY →